45
Participants
Start Date
March 10, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
July 31, 2026
CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF-19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
RECRUITING
Children's Hospital Colorado, Aurora
Children's Hospital Colorado
OTHER
University of Colorado, Denver
OTHER